// App-Quantinova.ai

217.0 : A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Researchers

Presenter

  • Eileen Mary O'Reilly

Principal Investigators

  • Do-Youn Oh

  • Neesha Dhani

  • Daniel John Renouf

  • Myung Ah Lee

  • Weijing Sun

  • George A. Fisher

  • Aram F. Hezel

  • Shao-Chun Chang

  • Gordana Vlahovic

  • Osamu Takahashi

  • Yin Yang

  • Philip Agop Philip

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • University of Kansas Medical Center, Kansas City, MO

  • University of Rochester, Rochester, NY

  • AstraZeneca, Gaithersburg, MD

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

Locations

  • United States

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ticilimumab

  • Gemcitabine

  • Durvalumab

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • NCT02558894

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved